Switzerland· 67109008

Imbruvica

A ibrutinib product containing ibrutinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC L01EL01

Checked against BAG Spezialitätenliste (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHBAG Spezialitätenliste (Switzerland)normalisedImbruvicaATCL01EL01REGISTER NO.67109008PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Ibrutinib is registered in 13 of 19 countries.

Countries holding a registration under ATC L01EL01 (ibrutinib), each read from that country’s own register.

  • This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
  • 8 of them publish a price we can compare per daily dose

Ibrutinib · ATC L01EL01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ibrutinib costs, country by country.

Normalised to the WHO defined daily dose (0.42 g), the median price runs from $4.92 in France to $193.73 in Switzerland — a ×39 gap.

  • Switzerland: $193.73 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Ibrutinib · price per daily dose (0.42 g)

USD · FX 28 Sept 2026

  • CH Switzerland$193.73
  • FR France$4.92
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

BAG Spezialitätenliste (Switzerland)
Active substance
ibrutinibum
Manufacturer
—
Country
Switzerland (CH)
ATC code
L01EL01
ATC class
Ibrutinib
Defined daily dose
0.42 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
BAG Spezialitätenliste (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680671090086
    28 Stk
    CHF 5940.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

370 interactions on record for ibrutinib.

Graded by severity as the source publishes them — 189 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ibrutinib · interactions on record

370 records

  • 189 severe
  • 177 moderate
  • 4 minor

Most severe, free to view

  • AprepitantA04AD12severe
  • LinseedA06AC05severe
  • LonafarnibA16AX20severe
  • DicoumarolB01AA01severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ibrutinib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ibrutinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Imbruvica
  • Liechtenstein · Imbruvica
  • Norway · Imbruvica

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9a013d7b-cd68-4b2e-aa9c-bd335db75af8
GET /v1/drugs/9a013d7b-cd68-4b2e-aa9c-bd335db75af8?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "ibrutinibum 560 mg",
  "valid_from": "2021-11-01",
  "limitations": "[{\"description\":\"lbrutinib wird nicht bei Patienten vergütet, bei denen unter BTK-lnhibitoren eine Krankheitsprogression auftrat.<br>\\nDie Behandlung bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-05-01\",\"validTo\":null},{\"description\":\"<b>Mantelzelllymphom (MCL, Monotherapie)</b><br>\\nAls Monotherapie zur Behandlung von erwachsenen Patienten mit MCL, charakterisiert durch Translokation t(11;14) und/oder Expression von Cyclin D1, in denen kein partielles Ansprechen erreicht wurde mit vorheriger Therapie oder die eine Progression nach der vorherigen Therapie gezeigt haben.<br>\\n<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21011.07<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21011.07\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2023-05-01\",\"validTo\":null}]",
  "galenic_form": "Filmtabl 560 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2021-11-01",
  "self_retention_pct": 10
}

See everything about ibrutinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.